News Image

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Provided By GlobeNewswire

Last update: Jul 29, 2025

– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community –

Read more at globenewswire.com

EYEPOINT PHARMACEUTICALS INC

NASDAQ:EYPT (11/14/2025, 8:00:01 PM)

After market: 11.58 0 (0%)

11.58

+0.07 (+0.61%)



Find more stocks in the Stock Screener

EYPT Latest News and Analysis

Follow ChartMill for more